Literature DB >> 24673794

Comparing female-based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population.

Ediz Dalkilic1, Ayse Nur Tufan, Mustafa Ferhat Oksuz, Mustafa Sahbazlar, Belkis Nihan Coskun, Nihan Seniz, Yavuz Pehlivan, Murat Inanc.   

Abstract

AIM: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is 10 times more prevalent in women, particularly those of reproductive age. The varying effects of pregnancy on SLE and the differences between available SLE treatments make pregnancy timing and contraceptive methods significant. We aimed to determine the contraceptive methods used by SLE patients in the north-west part of Turkey, and compared them with those used by rheumatoid arthritis (RA) patients and healthy controls.
METHOD: The study was comprised of 113 SLE patients, and 84 RA patients at the Rheumatology Outpatient Clinic of Uludag University Medical Faculty.
RESULTS: Twenty-three (20.3%) out of 113 SLE patients, 18 (21.4%) out of 84 RA patients and 17 (18.6%) out of 92 healthy controls did not use any contraceptive methods. Use of the withdrawal and condom methods was more common among SLE patients, accounting for 61% (withdrawal 32.7%, condom 28.3%). Moreover, 52% of SLE and 50% of RA patients were neither given information about contraceptive methods nor offered a suggested method, compared to 34% in the health control group.
CONCLUSIONS: The prevalence of oral contraceptive use is low in Turkey; notwithstanding the withdrawal and condom methods, which are frequently used despite their high failure risk. Although pregnancy timing is of great importance for SLE patients, necessary information and recommendations concerning contraceptive methods have been ignored and the use of effective methods is not a priority.
© 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  contraception; rheumatoid arthritis; systemic lupus erythematosus

Mesh:

Substances:

Year:  2014        PMID: 24673794     DOI: 10.1111/1756-185X.12338

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  6 in total

1.  Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis.

Authors:  David L Leverenz; Amanda M Eudy; Malithi Jayasundara; Tayseer Haroun; Gary McDaniel; W Benjamin Nowell; Jeffrey R Curtis; Rachelle Crow-Hercher; Whitney White; Seth Ginsberg; Megan E B Clowse
Journal:  Clin Rheumatol       Date:  2019-01-16       Impact factor: 2.980

Review 2.  A systematic review of interventions to improve knowledge and self-management skills concerning contraception, pregnancy and breastfeeding in people with rheumatoid arthritis.

Authors:  Ilana N Ackerman; Gene-Siew Ngian; Sharon Van Doornum; Andrew M Briggs
Journal:  Clin Rheumatol       Date:  2015-12-05       Impact factor: 2.980

3.  Effectiveness of reproductive health counseling of women with systemic lupus erythematosus: observational cross-sectional study at an academic lupus clinic.

Authors:  Luisa Brites; Stefanie Silva; Laura Andreoli; Luis Inês
Journal:  Rheumatol Int       Date:  2020-08-07       Impact factor: 2.631

4.  Patterns of contraceptive use among young Australian women with chronic disease: findings from a prospective cohort study.

Authors:  Melissa L Harris; Nicholas Egan; Peta M Forder; Deborah Bateson; Aaron L Sverdlov; Vanessa E Murphy; Deborah Loxton
Journal:  Reprod Health       Date:  2022-05-07       Impact factor: 3.355

5.  Contraceptive Prevalence and Consulting Service in Women with Systemic Lupus Erythematosus: A Cross-Sectional Study.

Authors:  Maryam Mobini; Reza Ali Mohammadpour; Yasaman Salehi; Fatemeh Niksolat
Journal:  Ethiop J Health Sci       Date:  2021-03

6.  Racial Differences in Contraception Encounters and Dispensing Among Female Medicaid Beneficiaries With Systemic Lupus Erythematosus.

Authors:  Jessica N Williams; Chang Xu; Karen H Costenbader; Bonnie L Bermas; Lydia E Pace; Candace H Feldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-02       Impact factor: 5.178

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.